SPOTLIGHT: Nastech restructuring to claim up to 75 jobs

In yesterday's report on Nastech's restructuring, we cited a story that included a reference to the biotech's 197 staffers, which was the payroll number at the beginning of the year. A spokesperson adds that the company had since expanded to 230 workers. Of those, up to 75 will be laid off as the company restructures in the wake of P&G's decision to terminate a $577 million development pact for Nastech's osteoporosis therapy. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.